Tapered titanium cementless total hip replacements: a 10- to 13-year followup study.

The 10- to-13 year performance of 307 Mallory Head cementless tapered total hip replacements in 283 patients was assessed. Eighty-five percent of patients had a diagnosis of osteoarthritis. Fifty-one percent of patients were women. The mean patient age was 64 +/- 10 years. The Hex Loc cementless acetabular component and titanium alloy femoral heads were used in each patient. At final followup, 37 (13%) patients died, 32 (10%) had revision surgery, and two (1%) were lost to followup. No femoral stem was revised for aseptic loosening, but one was revised because of sepsis and one was revised because of a periprosthetic fracture. Wear, osteolysis, and loosening were problems with the Hex Loc cementless acetabular components and 31 (10%) acetabular components required revision because of these mechanisms. The mean Harris hip score at final followup of the remaining patients was 87 +/- 14 points. Three percent of these patients had thigh pain. Radiographic assessment revealed that no femoral stem or acetabular socket was definitely or probably loose. Three-dimensional wear assessment using the Devane technique was 0.35 mm per year. The Mallory Head cementless, tapered femoral component performed well in the patients in the current study, but unfortunately, the clinical results were compromised by the use of a suboptimal cementless acetabular component, the use of polyethylene that was gamma-irradiated in air, and by the use of titanium alloy femoral heads. Future developments obviously will be in the areas of better acetabular component design, alternate polyethylene sterilization methods, and enhancements of the femoral stem in terms of offset choices, neck design, and perhaps ingrowth surface.     

Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors

RNA-binding protein IMP3 is a KH-domain-containing protein and a member of the insulin-like growth factor messenger RNA-binding protein family. It is identical to K-homology protein overexpressed in cancer that was identified through screening for genes differentially expressed between benign pancreatic tissue and pancreatic cancer. Several studies have shown that IMP3 is associated with aggressive and advanced tumors in various organs. We studied the expression of IMP3 in benign urothelium and urothelial tumors by immunohistochemistry. The expression pattern of IMP3 was further compared with that of p53 and p16. Our study shows that IMP3 is generally not expressed in benign urothelium or low-grade urothelial tumors including urothelial dysplasia, papillary urothelial neoplasm of low malignant potential, and low-grade papillary urothelial carcinoma. The expression of IMP3 is significantly increased in high-grade urothelial tumors including high-grade papillary urothelial carcinoma, urothelial carcinoma in situ, and invasive urothelial carcinoma. Expression of IMP3 in urothelial tumors parallels the accumulation of nuclear p53, although there is not always a one to one correlation. In contrast, expression of p16 in the different groups of urothelial tumors is more variable. Urothelial carcinomas with invasion of muscularis propria appear to express IMP3 more frequently than lower-stage tumors. These findings suggest that IMP3 may be involved in the progression of urothelial tumors from low grade to high grade in both papillary and flat lesions. Immunohistochemical detection of the combined expression of IMP3 and p53 is useful in the diagnosis of high-grade urothelial tumors, particularly in small, superficial materials.     

Identification of WASP mutations in 10 Australian families with Wiskott-Aldrich syndrome and X-linked thrombocytopenia

Mutations of the gene encoding the Wiskott-Aldrich syndrome protein (WASP) have been previously shown to be responsible for classical Wiskott-Aldrich syndrome (WAS), isolated X-linked thrombocytopenia (XLT) and severe congenital X-linked neutropenia. AIMS: Identification of WASP mutations in 10 unrelated Australian families presenting with clinical features of WAS/XLT. METHODS: Mutation analysis was performed by PCR and sequence analysis. RESULTS AND CONCLUSIONS: Two novel mutations and seven mutations which have previously been reported were identified. The novel mutations consisted of a missense mutation in exon 2 (C290A) associated with the phenotype of XLT and a mutation in intron 10 (1372+1G>A) in the mother of two boys presenting with a classical WAS phenotype.     

Endothelium in hepatic cavernous hemangiomas does not express the hyaluronan receptor for endocytosis

The liver contains two distinct endothelial cell types: vascular and sinusoidal. Although cavernous hemangioma is the most common benign tumor of the liver, vascular or sinusoidal endothelial cell differentiation has not been described. An endocytic receptor responsible for the uptake and degradation of hyaluronan is present in the sinusoidal endothelium of the liver. The hyaluronan receptor for endocytosis (HARE) may therefore be a useful marker for sinusoidal endothelial cell differentiation. Using monoclonal antibodies specific for HARE, CD31, and factor VIII, we completed an immunohistochemical study of the endothelial cells of both hepatic cavernous hemangiomas and of nonneoplastic human liver. The anti-HARE monoclonal antibodies showed diffuse strong staining of nonneoplastic liver sinusoidal endothelium. No staining of nonsinusoidal endothelium or the endothelial lining of the hemangiomas was seen with anti-HARE. In contrast, diffuse strong staining for factor VIII and CD31 was present in nonsinusoidal endothelium and cavernous hemangioma endothelium. Neither factor VIII nor CD31 staining was present in the sinusoidal endothelium. In conclusion, the endothelium of hepatic cavernous hemangiomas demonstrates vascular but not sinusoidal differentiation based on the absence of HARE and presence of CD31 and factor VIII.